SVRA Share Price | Savara, Inc. Stock Analysis & Recommendation

Q: How big is Savara, Inc.?

Market Cap: As of Jun 18, Savara, Inc. has a market capitalization of 352.59 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Savara, Inc. reported net sales of 0.00 million and a net profit of -102.17 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 171.45 million and total assets of 212.88 million.

Q: What does Savara, Inc. do?

Overview: Savara, Inc. is an orphan lung disease company engaged in the development and commercialization of novel therapeutics in the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Net Profit: -27 Million (Quarterly Results - Mar 2025) Market cap: USD 352.59 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.97 Return on Equity: -68.74% Price to Book: 2.38Contact Details: Address: 900 S Capital of Texas Hwy Ste 150, WEST LAKE HILLS TX: 78746-5436 Tel: 1 512 6141848 Website: http://savarapharma.com/

Q: Is Savara, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Savara, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI is bearish on the weekly timeframe, but there is no signal on the monthly. Bollinger Bands show a mildly bullish stance weekly and mildly bearish monthly. Daily moving averages are bullish, supporting a positive short-term outlook. KST is bullish weekly but bearish monthly, and Dow Theory indicates no trend weekly and mildly bullish monthly. In terms of performance, Savara has outperformed the S&P 500 over the past month (10.44% vs. 3.95%) and year-to-date (13.68% vs. 13.31%), but it has underperformed over the past year (-22.27% vs. 16.64%). Overall, the current technical stance is mildly bullish, with key indicators such as the daily moving averages and weekly MACD contributing positively, despite mixed signals from other indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.22 M

Shareholding (Sep 2025)

FII

6.20%

Held by 78 FIIs

DII

24.95%

Held by 37 DIIs

Promoter

50.86%

How big is Savara, Inc.?

22-Jun-2025

As of Jun 18, Savara, Inc. has a market capitalization of 352.59 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -102.17 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 171.45 million and total assets of 212.88 million.

View full answer

What does Savara, Inc. do?

22-Jun-2025

Savara, Inc. is a pharmaceutical company focused on developing and commercializing treatments for orphan lung diseases. As of March 2025, it has a market cap of $352.59 million and reported a net profit loss of $27 million.

View full answer

Who are in the management team of Savara, Inc.?

22-Jun-2025

As of March 2022, the management team of Savara, Inc. includes Mr. Matthew Pauls as Chairman and CEO, along with independent directors Mr. Nevan Elam, Mr. Richard Hawkins, Dr. Joseph McCracken, Mr. David Ramsay, and Mr. Ricky Sun.

View full answer

Is Savara, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Savara, Inc. shows a mildly bullish trend with positive short-term indicators, despite mixed signals from longer-term metrics and underperformance over the past year compared to the S&P 500.

View full answer

Compare Savara, Inc. with Similar Stocks

Olema Pharmaceuticals, Inc.Harrow, Inc.Evolus, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,259 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-121.94%

Price to Book

13.34

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-30 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

101.5%

6 Months

59.52%

1 Year

28.54%

2 Years

65.94%

3 Years

280.14%

4 Years

186.63%

5 Years

92.81%

Savara, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-180.93%

EBIT to Interest (avg)

-58.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.97

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.85

EV to EBIT

-2.55

EV to EBITDA

-2.56

EV to Capital Employed

55.83

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-2185.31%

ROE (Latest)

-68.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 34 Schemes (17.98%)

Foreign Institutions

Held by 78 Foreign Institutions (6.2%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -22.31% vs -45.78% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.20",
          "val2": "-26.30",
          "chgp": "-14.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.60",
          "val2": "-24.20",
          "chgp": "-22.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.32% vs -43.57% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.90",
          "val2": "-59.80",
          "chgp": "-72.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-95.90",
          "val2": "-54.70",
          "chgp": "-75.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-30.20

-26.30

-14.83%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-29.60

-24.20

-22.31%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -22.31% vs -45.78% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-102.90

-59.80

-72.07%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-95.90

-54.70

-75.32%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -75.32% vs -43.57% in Dec 2023

All Annual Results

Company CV

About Savara, Inc.

Savara, Inc.

Pharmaceuticals & Biotechnology

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.

Company Coordinates

Company Details

900 S Capital of Texas Hwy Ste 150 , WEST LAKE HILLS TX : 78746-5436

Tel: 1 512 6141848

http://savarapharma.com/

Registrar Details

Savara, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Savara, Inc.?

Watch in Real-Time

What does Savara, Inc. do?

Who are in the management team of Savara, Inc.?

Is Savara, Inc. technically bullish or bearish?

Compare Savara, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Savara, Inc.

Company Coordinates